GPT and steatosis: Developing new models and improving the existing models are needed due to the poor specificity of the routinely used blood test (ie, ALT) to screen MASLD, the poor diagnostic performance of ultrasonography-based techniques, particularly in patients with low-grade steatosis, and the cost associated with MRI-based tools in epidemiological studies.